Every beta-2 agonist ever tested for muscle growth hits the same wall: desensitization. Dr. Tore Bengtsson built one that doesn't.
A professor at Stockholm University and founder of Atrogi, Dr. Bengtsson has spent 25 years studying how beta-adrenergic receptors regulate metabolism, muscle, and brown fat. His lab developed 1,500+ compounds that activate beta-2 through distinct signaling pathways, and one is now heading into Phase 2 clinical trials. He shares how a "failed" experiment cracked the problem, why incretins only address half of metabolic disease problems, and what muscle loss after 50 means for drug discovery strategy.
Key takeaways:
Classical beta-2 agonists fail because desensitization shuts down the response
Selectively activating specific signaling pathways from one receptor can produce entirely different outcomes
Incretins reduce energy intake — but the energy expenditure side remains wide open
The correlation between muscle mass and longevity is one of the most underserved areas in metabolic medicine
Podden och tillhörande omslagsbild på den här sidan tillhör
Dr. Yamina Berchiche. Innehållet i podden är skapat av Dr. Yamina Berchiche och inte av,
eller tillsammans med, Poddtoppen.
